In autumn 2015 BÜHLMANN will launch a new generation of faecal calprotectin assay. The BÜHLMANN fCAL™turbo, the next step in automation of faecal calprotectin quantification.
Fecal calprotectin (fCAL) is the most important marker for in vitro diagnostic detection of gut inflammation. Immunological quantitation is well established and is used in the diagnostic work-up of inflammatory bowel diseases (IBD) and in the life long monitoring of these chronic conditions.
fCAL testing today demands for a raised level of lab resources including stool sample handling, extraction and the use of traditional immunological testing methods.
The BÜHLMANN fCAL™ turbo assay is a big step towards total automation. It reduces the time to result significantly to only ten minutes, offers random access and is independent of the clinical chemistry platform. The well-established assay format of particle-enhanced turbidimetric immunoassay (PETIA) further increases the precision and reproducibility of calprotectin quantification.
The combination with the proprietary extraction device CALEX® Cap for pre-analytic sample preparation simplifies and accelerates stool diagnostic, significantly. The BÜHLMANN fCAL™turbo utilize the well-established standardization of the BÜHLMANN fCAL™ ELISA to provide reliability and continuity of measurements.